SEC Tracker
Get the app

Artiva Biotherapeutics ARTV

Artiva Biotherapeutics halts AlloNK development

Item 2.02 Reports results, Item 2.05 Exit or restructuring costs

Form
8-K
Filed
Importance
Major
  1. Preliminary cash, cash equivalents, and investments of $319.1M as of Sept 30, 2026
  2. Plans to reduce workforce by 94%
  3. Discontinuation of AlloNK (AB-101) development
  4. Wind down costs expected in Q4 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Artiva Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  2. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  3. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  4. Pluri PLUR public float $15M, Dec 31, 2025
  5. CalciMedica CALC public float $16M, Jun 30, 2025